Prostatic Neoplasms, Castration-Resistant Recruiting Phase 1 / 2 Trials for Cetrelimab (DB15421)

IndicationStatusPhase
DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03431350A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerTreatment